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ABSTRACT
Administration of phosphodiesterase 4 (PDE4) inhibitors sup-
presses the pathogenesis associated with experimental auto-
immune encephalomyelitis (EAE), an animal model of multiple
sclerosis (MS). In the present study, we compared the effects
of rolipram and 4-[2-(3,4-bis-difluoromethoxyphenyl)-2-[4-
(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-
3-methylpyridine-1-oxide (L-826,141), a novel nonbrain pene-
trant PDE4 inhibitor, on the onset and severity of clinical signs
in a chronic, nonrelapsing/remitting model of EAE. Both
rolipram (10 mg/kg p.o.) and L-826,141 (3 mg/kg p.o.) reduced
the severity of EAE relative to controls, whereas L-826,141 (3
mg/kg p.o.) also delayed disease onset. To assess whether
L-826,141 prevented EAE progression after the first signs of
clinical onset, rolipram (10 mg/kg p.o.) or L-826,141 (3 or 30
mg/kg p.o.) were administered 24 h after the first signs of EAE
were observed. Only L-826,141 at a dose of 30 mg/kg p.o.
significantly decreased the clinical severity of EAE compared
with vehicle controls. Immunohistochemical detection of the
neuronal activity marker Fos confirmed that L-826,141 did not
reach concentrations in the central nervous system sufficient to
activate central neurons. Lipopolysaccharide-induced tumor
necrosis factor- in whole blood and plasma concentrations of
L-826,141 revealed that only the 30-mg/kg dose resulted in
levels sufficient to produce a near complete inhibition of PDE4
activity in immune cells. Taken together, these results demon-
strate that peripheral PDE4 inhibition, produced by L-826,141,
prevents the progression of EAE after the first onset of clinical
signs, and suggest that similar compounds may have clinical
efficacy in the treatment of MS.
Multiple sclerosis (MS) is one of the most common neuro-
logical autoimmune diseases, affecting more than 2.5 million
people worldwide. This disease is characterized by the loss of
oligodendrocytes, the myelin-producing cells in the central
nervous system (CNS), resulting in impaired axonal conduc-
tion and neurological deficits (Bjartmar and Trapp, 2003;
Fassas and Nash, 2004). Unfortunately, many of the current
treatments for MS are costly, administered subcutaneously,
limited in efficacy, and occasionally cause postinjection site
irritation/infection. The development of an orally active drug
that is well tolerated and slows disease progression would be
a significant improvement in the treatment of MS.
Experimental autoimmune encephalomyelitis (EAE) is a
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predominantly Th1 cell-mediated autoimmune disease that
is used as a model of MS in both rodents and nonhuman
primates. Traditionally, EAE is induced by immunizing an-
imals with specific myelin antigens, resulting in an immune
response against the recognized antigen. The combination of
myelin antigen and animal species/strain often predicts the
clinical course of EAE, albeit chronic, acute, or relapsing-
remitting (von Budingen et al., 2002). The pathological fea-
tures of EAE are similar to those that are observed in MS,
including blood-brain barrier breakdown, infiltration of im-
mune cells in the CNS, inflammation, and demyelination
(Floris et al., 2004; Pomeroy et al., 2005).
Phosphodiesterases (PDEs) are enzymes responsible for
regulating levels of cyclic nucleotides, in particular cAMP
and cGMP, which are important secondary messengers in-
volved in molecular signaling. In particular, PDE4 is a
cAMP-specific isoenzyme family of PDEs that is predomi-
nantly expressed in many inflammatory cells (Schudt et al.,
1995). In immune cells, elevations in cAMP reduce cell mo-
tility (Layseca-Espinosa et al., 2003) and attenuate immune
cell activation (Souness et al., 2000). Previously, PDE4 in-
hibitors have been used for suppressing inflammation in
animal models of arthritis, chronic obstructive pulmonary
disease, heart disease, and MS (Burnouf and Pruniaux, 2002;
Hamamoto et al., 2004). The anti-inflammatory properties of
PDE4 inhibitors have also led investigators to assess their
therapeutic potential in a variety of human inflammatory
and autoimmune diseases, including rheumatoid arthritis
(Tenor et al., 2002) and asthma (Compton et al., 2001).
In immune cells, inhibition of PDE4 prevents cAMP deg-
radation, thus elevating cAMP levels and inhibiting the pro-
duction and release of proinflammatory cytokines from acti-
vated peripheral mononuclear cells, including but not limited
to, tumor necrosis factor (TNF)-, interleukin (IL)-2, IL-12,
and interferon (IFN)- (Kaminuma et al., 1998; Muise et al.,
2002; Claveau et al., 2004). Consequently, TNF- concentra-
tions have been used as a surrogate marker for examining
inhibition of PDE4 activity (Muise et al., 2002). More re-
cently, the enzymes encoded by the PDE4 splice variants
PDE4A, PDE4B, and PDE4D are thought to be largely re-
sponsible for total PDE4 activity (Giembycz et al., 1996). In
particular, PDE4B induction has been shown to be essential
for LPS-activated TNF- responses in vivo (Jin and Conti,
2002). In terms of selectivity, L-826,141 (for structure, see
Claveau et al., 2004) is a highly selective PDE4 inhibitor that
has been to shown to be at least 450-fold more potent at
inhibiting PDE4 versus PDE1–11 (Claveau et al., 2004).
The prototypical PDE4 inhibitor rolipram, initially devel-
oped as an antidepressant, has potent anti-inflammatory
properties in models of allergic and autoimmune disease,
including EAE (Sommer et al., 1995; Jung et al., 1996).
Rolipram readily crosses the blood-brain barrier, resulting in
emetic side effects, which have hampered the clinical devel-
opment of this compound (Robichaud et al., 2001). Newer
PDE4 inhibitors, such as L-826,141, are significantly less
brain penetrant and do not display emesis at doses that are
anti-inflammatory (Frenette et al., 2002). In addition, ferrets
fail to display emesis when orally administered 30 mg/kg
L-826,141 (Frenette et al., 2002). In the rat, L-826,141 is well
absorbed and possesses a bioavailability of 60% when deliv-
ered orally at 3 mg/kg. The anti-inflammatory effects of
L-826,141 (1 mg/kg i.p.) have been demonstrated in a guinea
pig asthma model of ovalbumin-induced bronchoconstriction
and in a squirrel monkey model of antigen-induced broncho-
constriction (0.5–3 mg/kg) (Muise et al., 2002).
The purpose of the present study was to determine
whether oral administration of L-826,141 was sufficient to
delay and/or decrease the clinical symptoms associated with
EAE. The doses of L-826,141 used in this experiment were
chosen based on their ability to suppress LPS-induced TNF-
release in mouse whole blood. Here we show that L-826,141
prevents the development of EAE when administered before
and after the first clinical signs are apparent. Our results
suggest that PDE4 activity in EAE was not mediated by
central inhibition of PDE4 activity but rather in the pe-
riphery.
Materials and Methods
Reagents. The PDE4 inhibitor rolipram [4-[3-(cyclopentyloxy)-4-
methoxy-phenyl]pyrrolid-2-one] was purchased from A.G. Scientific,
Inc. (San Diego, CA). L-826,141 was synthesized and supplied by
Merck Frosst (Montreal, QC, Canada). Both compounds were sus-
pended in 1% methylcellulose and underwent sonication for 30 min
at 4°C before administration.
LPS-induced TNF- Release Whole-Blood Assay. C57BL/6
mice were dosed orally with L-826,141 (3 and 30 mg/kg) and vehicle
every 24 h for 3 days. At trough levels, whole blood was collected into
microtainers containing lithium heparin (BD Biosciences, Franklin
Lakes, NJ). LPS (serotype 0111:B4; Sigma-Aldrich, St. Louis, MO)
derived from Escherichia coli (100 g) was used to induce the release
of TNF-, a surrogate marker for PDE4 activity in mouse whole
blood. Freshly prepared LPS was prepared at a concentration of 5
mg/ml in 0.1% bovine serum albumin in phosphate-buffered saline
and diluted to a final concentration of 100 g of LPS/ml of blood. The
blood was incubated for 4 h at 37°C in a humidified tissue culture
incubator supplemented with 5% CO2. Following this incubation,
blood was centrifuged at 1400g for 10 min at 4°C, and the plasma
was collected and stored at 80°C.
As a method for determining the optimal dose for administering
L-826,141 to EAE-immunized mice, the suppression of LPS-induced
TNF- release in whole blood was assessed using an ELISA and
performed according to the manufacturer’s protocol (BioSource In-
ternational, Camarillo, CA). In brief, using a solid-phase sandwich
ELISA and a streptavidin-peroxidase reaction, the intensity of the
colored product is directly proportional to the amount of TNF- in
the sample. The absorbance was read at 450 nm blanked against a
chromagen blank, and the amount of TNF- in each sample was
calculated using a recombinant mouse TNF-.
Determination of Plasma Concentrations of L-826,141.Mice
were orally dosed every 24 h for three consecutive days, and plasma
was collected 24 h after the last dose. Samples were stored at 80°C
until they were analyzed by liquid chromatography-mass spectrom-
etry (B9-atmospheric pressure chemical ionization) with an internal
standard (Merck Frosst Centre for Therapeutic Research, Kirkland,
QC, Canada).
Induction of EAE. EAE studies were performed on 6 to 8-week-
old female C57BL/6 mice (Charles River Canada, Montreal, QC,
Canada). Animals were housed with access to food and water ad
libitum on a 12-h light/dark cycle. All protocols used in this experi-
ment were conducted in accordance with approval by the University
Committee on Laboratory Animals at Dalhousie University (Halifax,
NS, Canada) in accordance with the guidelines set by the Canadian
Council on Animal Care.
Mice were immunized with a 1:1 ratio of myelin oligodendrocyte
glycoprotein (MOG) encephalitogenic peptide amino acids 35 to 55
(MOG35-55) (Sheldon Biotechnology Centre, Montreal, QC, Canada)
dissolved in 0.9% saline and Complete Freund’s adjuvant (CFA)
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containing 0.5 mg of Mycobacterium tuberculosis H37RA (Difco; BD
Diagnostics). On day 0, the MOG-CFA emulsion was administered
subcutaneously on both sides at the base of the tail (100 g/mouse).
The additional immune adjuvant pertussis toxin (Sigma-Aldrich) in
1 Hanks’ balanced salt solution was injected i.p. (200 ng/mouse) on
the initial day of immunization and again on day 2. On day 7, the
MOG  CFA immunization was repeated, with two subcutaneous
injections into the upper flanks of each mouse.
Care and Clinical Evaluation of EAEMice. The weights of the
mice were recorded daily, and the clinical scores of the animals were
assessed over the duration of 21 days. The following grading scheme
was used to clinically score the animals: 0, no clinical signs; 0.5, hook
tail; 1, flaccid/floppy tail; 2, beginning of walking deficits; 3, unilat-
eral hindlimb paralysis; 4, bilateral hindlimb paralysis; and 5, mor-
ibund. Clinical scoring was performed by two qualified individuals,
one individual who was unaware of the treatment group. No signif-
icant differences were recorded between the recorded scores between
the blinded and unblinded scorer. Mice were supplied with mash
when they were no longer able to reach the food and water. Neutrical
was also provided to mice as an additional nutrient supplement.
Rolipram and L-826,141 Administration. Rolipram (10 mg/kg),
L-826,141 (3 mg/kg), or 1% methylcellulose (10 ml/kg) was used as the
vehicle control and was administered daily by oral gavage beginning on
day 9 (n  12 mice/group). A second control group of immunized ani-
mals (n  12) was not gavaged to assess the impact of gavage-induced
stress on EAE severity. The two treatment groups receiving the PDE4
inhibitors were administered the compounds daily, for 12 days, until
day 21, at which point the animals were sacrificed. To assess the effect
of L-826,141 on decreasing EAE severity after the onset of clinical signs,
mice were administered L-826,141 (3 mg/kg p.o.; n  24), rolipram (10
mg/kg p.o.; n  24), or vehicle (n  16) 24 h after the onset of clinical
signs of EAE, and they were dosed daily for the duration of the exper-
iment. In this experiment, all mice were immunized on day 0; however,
drug/vehicle treatment did not begin until each individualized mouse
began to develop signs of EAE; thus, initiation of compound adminis-
tration occurred over a period of days.
To determine whether an increased dose of L-826,141 had an
impact on EAE severity, mice were either administered L-826,141 (30
mg/kg p.o.; n 8) or vehicle (n 11) 24 h after the onset of clinical signs
of EAE and dosed daily for the duration of the experiment
Histology. To examine for the presence of cellular infiltrates and
perivascular cuffing, an H&E stain was performed. Mice were deeply
anesthetized using sodium pentobarbital and transcardially per-
fused using 10 ml of saline and fixed using 4% PFA in PB. The brains
and spinal cords of animals were removed and postfixed in 4% PFA
and stored at 4°C. Before sectioning brains and spinal cords, the
tissues were cryoprotected in 30% sucrose in PB. Sagittal spinal cord
sections (14 m) were cut on the cryostat and stained with Mayer’s
hematoxylin and eosin (Sigma-Aldrich). In addition, sections were
stained with FluoroMyelin Green fluorescent myelin stain and DAPI
nucleic acid stain (Invitrogen, Carlsbad, CA) for assessment of de-
myelination and cellular infiltration.
c-fos and Glial Fibrillary Acidic Protein Immunohisto-
chemistry. Brains and spinal cords were dissected from mice that
received 3 mg/kg L-826,141, 10 mg/kg rolipram, or vehicle. Following
a postfixation in 4% PFA and cryoprotected in 30% sucrose solution
in PB, 30-m sections of brains were cut on a freezing microtome.
Brain sections were incubated for 30 min in a 1% H2O2 solution to
eliminate endogenous peroxidase activity. The tissue was then
blocked in 10% normal goat serum for 1 h at room temperature and
then incubated with a polyclonal rabbit anti-mouse c-fos antibody (1:
5000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at
4°C. Tissue sections were rinsed with 0.3% PBS-Triton X-100 and then
incubated with a biotinylated goat anti-rabbit secondary for 1 h at room
temperature (1:500; Vector Laboratories, Burlington, ON, Canada). The
tissue was subsequently exposed to an avidin-biotin-peroxidase com-
plex (ABC kit; Vector Laboratories) for 1 h and developed using a
glucose oxidase-stimulated diaminobenzidine reaction.
For examination of GFAP, spinal cord sections from mice that
received either L-826,141 (3 mg/kg p.o.) or vehicle beginning on day
9 were used. Spinal cord sections (14 m) were cut on the cryostat
and incubated in a Cy-3 conjugated monoclonal antibody against
glial fibrillary acidic protein antibody (1:1000) (Sigma-Aldrich) over-
night at 4°C.
Data Analysis and Statistics. The effect of varying doses of
L-826,141 on TNF- concentrations was analyzed using a one-way
analysis of variance (ANOVA) for independent groups corresponding
to different drug concentrations (three) Tukey’s honestly significant
multiple comparisons were used, and the 0.05 level of significance
was adopted for all comparisons.
The effect of varying doses of L-826,141 on blood plasma concen-
trations was analyzed using a one-way ANOVA for independent
groups, corresponding to different drug concentrations (three).
Tukey’s honestly significant multiple comparisons were used, and
the 0.05 level of significance was adopted for all comparisons.
Clinical scores and corresponding weights for mice were subjected
to separate one-way ANOVA for independent groups corresponding
to different drug treatments (L-826,141) with repeated measures
over days 0, 2, and 7 to 21. The overall ANOVA was followed by
analyses of the simple main effects of drug treatment performed on
independent days. Tukey’s honestly significant multiple compari-
sons were used where appropriate, and the 0.05 level of significance
was adopted for all comparisons.
Results
Plasma Concentrations of L-826,141 in C57BL/6 Mice
Dosed Orally at 3 and 30 mg/kg. Three groups of mice
were dosed with either vehicle, L-826,141 (3 mg/kg p.o.), or
L-826,141 (30 mg/kg p.o.) every 24 h for 3 days. Using mass
spectrometry, plasma levels of L-826,141 were determined
24 h after the last dose. Mice dosed with L-826,141 (3 mg/kg
p.o.) had an average plasma concentration of 0.035 0.007 M
(Fig. 1A). The average plasma concentration of L-826,141 in
mice dosed at 30 mg/kg p.o. was 0.81  0.08 M. As expected,
L-826,141 was not detectable in mice dosed with vehicle.
Oral Administration of L-826,141 (3 and 30 mg/kg) Sig-
nificantly Inhibits LPS-Induced TNF-Release inWhole
Blood fromC57BL/6Mice.Because TNF- is a proinflamma-
tory mediator, measuring this cytokine serves as an indication
of the efficacy of a molecule as an anti-inflammatory agent.
TNF- plasma concentrations can therefore be used as a surro-
gate marker for measuring the inhibitory action of a phospho-
diesterase 4 inhibitor (Muise et al., 2002). A baseline plasma
concentration of TNF- following LPS stimulation was mea-
sured using blood derived frommice treatedwith the vehicle 1%
methylcellulose. Mice were dosed daily with L-826,141 (3 or 30
mg/kg p.o.) every 24 h for 3 days, and blood was collected 24 h
after the last administration Inhibition of PDE4 activity was
assessed by measuring LPS-induced TNF- release using a
whole blood TNF- ELISA. Oral administration of L-826,141 (3
mg/kg p.o.) inhibited LPS-induced TNF- release in mouse
whole blood by nearly 50% (Fig. 1B). At a higher dose of
L-826,141 (30 mg/kg p.o.), TNF- release was inhibited by
nearly 90%. These results indicate that L-826,141 produced a
dose-dependent suppression of LPS-induced TNF- release in
mouse whole blood.
Oral Administration of L-826,141 (3 mg/kg) Prevents
Weight Loss, Delays Onset, and Decreases Severity of
EAEWhenAdministered before theOnset of the Clinical
Signs of EAE. Weight loss, onset, and severity of EAE were
assessed inmice treated with L-826,141 (3mg/kg p.o.), rolipram
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(10 mg/kg p.o.), or 1%methylcellulose (10 ml/kg p.o.), before the
onset of clinical signs of EAE. To control for the effects of
gavaging on EAE, an additional group of mice was immunized
and did not receive either drug or vehicle. The nongavaged and
1% methylcellulose control groups displayed no weight gain
over the duration of the experiment (Fig. 2A). In contrast, mice
administered L-826,141 (3 mg/kg p.o.) displayed an increase in
body weight compared with vehicle-treated mice. Rolipram-
treated animals (10 mg/kg p.o.) displayed a similar trend in
weight gain as the L-826,141-treated group. [drug, F(3,44) 
0.939, p  0.43; day, F(15,660)  1.755, p  0.192; and day 
drug, F(45,660)  5.271, p  0.003].
Mice administered L-826,141 (3 mg/kg p.o.) before the on-
set of EAE symptoms did not display clinical signs until day
17 (Fig. 2B). By contrast, mice treated with rolipram (10
mg/kg p.o.) and vehicle began to present clinical signs on day
10. The average clinical score of mice pretreated with
L-826,141 (3 mg/kg p.o.) or rolipram (10 mg/kg p.o.) was
lower compared with the control groups throughout the du-
ration of the experiment. Over the 3-week period, mice
treated with either L-826,141 or rolipram showed similar
clinical scores. In addition, the 1% methylcellulose and non-
gavaged control groups also showed similar clinical scores
throughout the experiment, suggesting that oral gavage does
not influence the onset or development of EAE. Following
EAE induction, the incidence of EAE was 17% in the group of
mice pretreated with L-826,141 (3 mg/kg p.o.) compared with
25, 67, and 75% of mice in the rolipram, vehicle, and nonga-
vaged control groups, respectively. Compared with the rolip-
ram and control groups, the onset of EAE was also delayed in
mice receiving L-826,141 (3 mg/kg p.o.) [drug, F(3,44) 
6.503 p  0.001; day, F(15,660)  36.442, p  0.001; and
day  drug, F(45,660)  5.609, p  0.002].
Oral Administration of L-826,141 (3 mg/kg) or Rolip-
ram (10 mg/kg) Does Not Influence EAE Severity When
Administered 24 h after the First Clinical Signs of
EAE. In a second set of experiments, three groups of mice
Fig. 1. A, plasma concentrations were obtained from mice dosed with
L-826,141 (3 or 30 mg/kg p.o.) or vehicle. Three groups of mice were orally
dosed with either vehicle, L-826,141 (3 mg/kg p.o.), or L-826,141 (30
mg/kg p.o.) every 24 h for 3 days, and plasma was collected. Mice dosed
with L-826,141 (3 mg/kg p.o.) had an average plasma concentration of
0.035  0.007 M. The average plasma concentration of L-826,141 in
mice dosed at 30 mg/kg p.o. was 0.81  0.08 M. Mice dosed with vehicle
had a plasma concentration of 0 mg/kg. , significantly different from
1% methylcellulose group at p  0.001. ‡‡‡, significantly different from
L-826,141 (3 mg/kg p.o.) group at p  0.001. B, TNF- concentration in
plasma of whole blood incubated with LPS, measured by an ELISA. Three
groups of mice were administered either 1% methylcellulose (n  3),
L-826,141(3 mg/kg; n  4), or L-826,141 (30 mg/kg; n  3) once daily for
3 days. Blood was collected 24 h after the final administration of either
drug or vehicle, and LPS-induced TNF- release was measured using a
mouse TNF- ELISA (BioSource International). Data are expressed as
the mean  S.E.M. , significantly different from vehicle group at p 
0.05; ‡, significantly different from 3-mg/kg group at p  0.01.
Fig. 2. Effects of orally administered PDE4 inhibitors rolipram (10 mg/kg)
and L-826,141 (3 mg/kg) on the average weight (A) and clinical scores (B) of
EAE-induced C57BL/6 mice. Four groups of mice were induced with EAE on
day 0 (n  12 mice/group) and vehicle (1% methylcellulose), or drug treat-
ments were administered daily from day 9 to 20. An additional group of EAE
mice was not gavaged. Data are expressed as the mean  S.E.M. , signif-
icantly different from 1% methylcellulose group at p  0.05.
66 Moore et al.
 at A






immunized with MOG35-55 were permitted to develop clinical
signs of EAE before administration of L-826,141, rolipram, or
vehicle. Rolipram (10 mg/kg p.o.), L-826,141 (3 mg/kg p.o.), or
vehicle was administered 24 h after the first appearance of
clinical signs of EAE. Throughout the duration of the exper-
iment, no differences in body weights were observed between
the three treatment groups (Fig. 3A) [drug, F(2,60)  2.393,
p  0.1; day, F(15,915)  0.018, p  0.893; day  drug,
F(30,900)  0.420, p  0.659]. In addition, no differences in
EAE severity were observed between the treatment groups
(Fig. 3B). Beginning on day 19, mice treated with L-826,141
(3 mg/kg p.o.) showed a nonsignificant trend for reduced EAE
severity, suggesting L-826,141 had a delayed degree of effec-
tiveness when administered after the onset of EAE. By con-
trast, mice treated with rolipram or vehicle did not seem to
show this trend after the onset of dosing [drug, F(2,60) 
1.599, p  0.211; day, F(15,900)  72.004, p  0.001; day 
drug, F(30,900)  1.080, p  0.346].
EAE Experiment 3. Oral Administration of L-826,141
(30 mg/kg p.o.) Suppresses Weight Loss and Decreases
EAE Severity When Administered 24 h after the Onset
of Clinical Signs of EAE. In a third experiment, mice
immunized with MOG35-55 were permitted to develop clinical
signs of EAE before oral administration of either L-826,141
(30 mg/kg p.o.) or vehicle. A rolipram treatment group was
omitted, because no obvious trend was observed when this
PDE4 inhibitor was administered 24 h after the onset of
clinical signs of EAE. Furthermore, signs of toxicity at the
10-mg/kg dose of rolipram prevented a further increase in
dosage. Mice were administered L-826,141 (30 mg/kg p.o.)
24 h after the first clinical signs of EAE and dosed daily for
the duration of the experiment. The average weight of mice
treated with vehicle declined over the duration of the exper-
iment. This trend was not observed in mice treated with
L-826,141 (30 mg/kg p.o.), indicative of overall increased
health in these mice (Fig. 4A) [drug, F(1,17)  3.011, p 
0.101; day, F(15,255)  4.120, p  0.058; day  drug,
F(15,255)  8.155, p  0.011].
Beginning on day 13, a notable difference in EAE severity
was observed between the groups that received either
L-826,141 (30 mg/kg p.o.) or vehicle (1% methylcellulose; 10
mg/kg p.o.). In contrast to the experiment where mice re-
ceived 3 mg/kg p.o., mice that received 30 mg/kg p.o. did not
develop clinical signs of EAE (Fig. 4B) [drug, F(1,17) 
Fig. 3. Effects of orally administered PDE4 inhibitors rolipram (10 mg/kg
p.o.) and L-826,141 (3 mg/kg p.o.) on the average weight (A) and clinical
scores (B) of EAE-induced C57BL/6 mice 24 h after the onset of the first
clinical signs of EAE. Three groups of mice were induced with EAE on day
0 and administered rolipram (10 mg/kg p.o.; n  24), L-826,141 (3 mg/kg
p.o.; n  24), or vehicle (1% methylcellulose; n  16). Data are expressed
as the mean  S.E.M.
Fig. 4. Effects of orally administered PDE4 inhibitor L-826,141 (30 mg/
kg) on the average weight (A) and clinical scores (B) of EAE-induced
C57BL/6 mice. Two groups of mice were induced with EAE on day 0 and
administered L-826,141 (30 mg/kg p.o.) 24 h after the onset of the first
clinical signs of EAE. Data are expressed as the mean  S.E.M. ,
significantly different from 1% methylcellulose group at p  0.05.
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22.140, p  0.001; day, F(15,255)  68.614, p  0.001; day 
drug, F(15,255)  29.243, p  0.001].
Histopathological Evaluation of L-826,141-Treated
Mice. To assess the effects of L-826,141 on the histopathol-
ogy of EAE, the spinal cords of vehicle and L-826,141-treated
animals were stained with H&E. Histopathological evalua-
tion was performed in mice from both the prophylactic and
therapeutic dosing studies. Immune cell infiltration and
perivascular cuffing were observed in the white matter of
spinal cords in mice that received vehicle (Fig. 5, A and B). A
marked absence of cellular infiltration was observed in ani-
mals administered L-826,141 (Fig. 5, C and D). Demyelina-
tion in the spinal cord was assessed using a FluoroMyelin
stain. Demyelinated lesions were apparent in the white mat-
ter of vehicle-treated animals (Fig. 6A). These areas of de-
myelination were accompanied by immune cell infiltration,
visualized by a nuclear DAPI stain (Fig. 6, B and C). A lack
of demyelination and cellular infiltration was observed in
mice treated with L-826,141 (Fig. 6, D–F). Regardless of the
dosing regime of L-826,141, the presence of cellular infil-
trates and demyelination was dependent on EAE clinical
severity. Increased cellular infiltration and demyelination
was observed in mice that were treated with L-826,141 (3
mg/kg p.o.) 24 h after disease onset. A notable decrease in
EAE histopathology was observed in mice dosed prophylac-
tically with L-826,141 (3 mg/kg p.o.) or therapeutically (30
mg/kg p.o.).
GFAP Immunoreactivity in the Spinal Cord of
L-826,141-Treated Mice. Previous studies have noted a
proliferation of astrocytes and reactive gliosis in the CNS of
animals with EAE (Aquino et al., 1988). Astrogliosis was
assessed in lumbar sections of the spinal cord using a mono-
clonal Cy3-conjugated GFAP antibody. A considerable
amount of GFAP immunoreactivity, indicative of astrogliosis,
was observed in the lumbar sections of vehicle-treated ani-
mals (Fig. 7A). A notable decrease in GFAP immunoreactive
cells was apparent in spinal cord sections from mice pre-
treated with 3 mg/kg L-826,141 (Fig. 7B). Increased GFAP
immunoreactivity was observed in mice were treated with
L-826,141 (3 mg/kg p.o.) 24 h after disease onset. A notable
decrease in GFAP was observed in mice dosed prophylacti-
cally with L-826,141 (3 mg/kg p.o.) or therapeutically (30
mg/kg p.o.).
Lack of Fos Immunoreactivity in the CNS of Symp-
tomatic Mice Treated with L-826,141. Fos is a putative
marker of neuronal activity and when detected immunohis-
tochemically, it is indicative of neuronal activation (Dra-
gunow and Faull, 1989). Rolipram, a prototypical PDE4
inhibitor, has been previously shown to increase Fos immu-
noreactivity in the nucleus accumbens shell and cortex in the
rodent brain (Svenningsson et al., 1995; Thompson et al.,
2004). The clinical efficacy of rolipram has been hindered by
its ability to cross the blood-brain barrier and subsequently
produce nausea and vomiting at therapeutic plasma concen-
trations (Krause and Kuhne, 1988; Burnouf and Pruniaux,
2002). Detection of PDE4 activity in the brains of animals
was assessed using a polyclonal antibody that selectively
recognizes Fos. Mice treated with vehicle showed no Fos
immunoreactivity in the deep and superficial layers of the
somatosensory cortex (Fig. 8A). Likewise, mice treated with
L-826,141 (3 mg/kg p.o.) also did not show any Fos staining
(Fig. 8B). Rolipram-treated mice (10 mg/kg p.o.) displayed
extensive Fos staining in the superficial and deep layers of
the somatosensory cortex (Fig. 8, C and D) and in the para-
ventricular nucleus of the dorsal thalamus (data not shown).
Discussion
The use of PDE4 inhibitors has been thoroughly investi-
gated as a novel treatment for chronic obstructive pulmonary
disease (Torphy et al., 1999) and rheumatoid arthritis (Sou-
ness et al., 2000). Accumulating evidence suggesting that
PDE4 inhibitors reduce EAE severity has led to the proposal
that such compounds may have therapeutic potential for
treating MS (Burnouf and Pruniaux, 2002). Unfortunately, a
complication with many PDE4 inhibitors is their ability to
readily cross the blood-brain barrier, accumulate in the CNS,
and trigger nausea and emesis (Duplantier et al., 1996;
Burnouf and Pruniaux, 2002). In this study, we have shown
that a novel nonbrain penetrant PDE4 inhibitor, L-826,141,
significantly delays the onset and severity of EAE adminis-
tered either before or after the initial onset of clinical symp-
toms.
LPS-induced TNF- release was used to determine the
dose of L-826,141 necessary to inhibit PDE4 activity in whole
blood. Assays performed in vitro have previously determined
that L-826,141 transcriptionally down-regulates TNF- in
whole-blood assays with an IC50 value of approximately 0.31
M (Claveau et al., 2004). L-826,141 has also been shown to
inhibit LPS-induced release of IL-12, granulocyte macroph-
age-colony-stimulating factor (GM-CSF), and IFN- (Claveau
et al., 2004). Oral administration of L-826,141 (3 mg/kg p.o.)
Fig. 5. Increased cellular infiltration and perivascular cuffing in the
spinal cords of vehicle-treated EAE mice. Spinal cord sections were
stained from vehicle-treated (A and B) and L-826,141 (3 mg/kg p.o.) (C
and D)-treated mice and stained using H&E. Perivascular cuffing, a
hallmark characteristic of MS and EAE, was observed in vehicle-treated
EAE mice (A and B). Scale bar, 200 m.
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Fig. 6. Areas of demyelination are accompanied by increased cellular infiltration in the spinal cords of symptomatic EAE mice. Spinal cord sections
from symptomatic EAE mice were stained with FluoroMyelin, a green fluorescent myelin stain (A) and nuclear counterstained using DAPI, which
specifically binds to DNA (B). An overlay of the two images (C) illustrates increased cellular infiltration of immune cells in demyelinated lesions of
areas in the spinal cord. Similar staining was performed on L-826,141-treated mice. Scale bar (D–F), 200 m.
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was sufficient to delay the onset and decrease EAE severity
when administered before the first appearance of clinical
signs; however, this dose did not significantly decrease clin-
ical signs when administered 24 h after the first onset of
clinical signs of EAE. When dosed at 3 mg/kg p.o., the plasma
concentration of L-826,141 was approximately 0.035 M at
trough (24 h). The known IC50 values of L-826,141 required
to inhibit the release of peripheral blood cytokines TNF-,
IL-2, GM-CSF, and IFN are approximately 0.88, 0.28, and
0.35 M, respectively (Claveau et al., 2004). Mice dosed with
L-826,141 (3 mg/kg p.o.) every 24 h for three consecutive days
had a plasma concentration of L-826,141 below the IC50
required to inhibit the release of proinflammatory cytokines
that are known to contribute to the pathogenesis of EAE. In
attempts to decrease EAE severity after clinical onset, a
higher dose of L-826,141 (30 mg/kg p.o.) was administered.
LPS-induced TNF- release whole-blood assays performed
using whole-mouse blood frommice treated with L-826,141 (3
or 30 mg/kg p.o.) demonstrated a dose-dependent decrease in
this measure of PDE4 activity. In contrast to the plasma
concentrations of L-826,141 in the mice dosed with 3 mg/kg
p.o., plasma concentrations achieved after dosing with 30
mg/kg p.o. were approximately 0.81 M, a concentration that
is greater than the IC50 required to inhibit TNF-, GM-CSF,
and IFN- release in LPS-induced mouse whole-blood assays.
L-826,141 (30 mg/kg p.o.) administered daily 24 h after the
first clinical signs of EAE prevented EAE progression. With
the exception of rolipram, to the best of our knowledge, this is
the first documentation of an orally administered nonbrain
penetrant PDE4 inhibitor that prevents the clinical signs of
EAE after disease onset. The average day of onset of EAE
in animals that received prophylactic administration of
L-826,141 (3 mg/kg p.o.) was significantly delayed compared
with rolipram (10 mg/kg p.o.) and vehicle-treated animals.
Using clinical scores and body weights as a method of assess-
ing the general health of the animals, mice pretreated with
L-826,141 seemed to remain healthy.
Nausea and emesis remain a large concern in the develop-
ment of PDE4 inhibitors (Duplantier et al., 1996). Although
rodents do not vomit, it is still possible to distinguish
whether the mice are experiencing discomfort as a direct
Fig. 7. Distribution of GFAP-positive cells in the lumbar regions of spinal
cords in mice treated with vehicle (A) and 3 mg/kg L-826,141 (B). Spinal
cord sections were stained with a Cy-3 conjugated GFAP monoclonal
antibody against GFAP and visualized using fluorescence microscopy. An
increase in GFAP-positive cells, indicative of astrogliosis, was noted in
the vehicle-treated symptomatic EAE mice compared with the asymp-
tomatic PDE4-treated mice. Scale bar, 200 m.
Fig. 8. Fos immunoreactivity in the cortex of mice dosed with vehicle (1%
methylcellulose) (A), L-826,141 (3 mg/kg p.o.) (B), and rolipram (10 mg/kg
p.o.) (C and D). D, high magnification of boxed in areas in C. Scale bar,
500 m (A–C) and 200 m (D). An increased level of c-fos immunoreac-
tivity was noted in the somatosensory cortex of rolipram-treated mice
compared with mice receiving either L-826,141 or vehicle.
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result of constant central PDE4 inhibition. We noted that
immediately following administration of rolipram, mice
showed visible signs of discomfort and lethargy (data not
shown). In addition, rolipram-treated mice were aversively
conditioned to the act of gavaging, suggestive of a learned
negative association between gavaging and the central ef-
fects of rolipram. This behavior was not observed in mice
treated with vehicle or L-826,141. In contrast, L-826,141-
treated mice became more compliant as oral delivery of the
drug was administered during the course of the experiment.
Rolipram possesses high affinity for its PDE4 binding sites
in the brain, in particular the area postrema (Carpenter et
al., 1988). In rodents, rolipram has previously been shown to
increase Fos expression in the cerebral cortex (Svenningsson
et al., 1995) caudate putamen, and nucleus accumbens
(Thompson et al., 2004). In addition, other agents that affect
intracellular cAMP, including forskolin and Ro 20-1724, a
PDE4 inhibitor, also stimulate c-fos gene expression (Haas et
al., 1991). Despite the ability of rolipram to suppress the
clinical signs of EAE (Sommer et al., 1997), the therapeutic
potential and clinical development of this compound is hin-
dered by its high emetic potential (Burnouf and Pruniaux,
2002). To test whether central PDE4 inhibition was occurring
in the brains off L-826,141-treated mice, levels of the puta-
tive neuronal activity marker Fos were assessed by immuno-
histochemistry 24 h after administration. Mice dosed with
rolipram (10 mg/kg p.o.) showed increased Fos immunoreac-
tivity in the somatosensory cortex and paraventricular re-
gions of the thalamus, compared with vehicle controls. In
L-826,141-treated mice, Fos immunoreactivity in the brain
was comparable with that of vehicle-treated animals. Be-
cause the blood-brain barrier is compromised in EAE, it may
be possible that L-826,141 could enter the CNS; however, we
think this is unlikely for the following reasons: 1) animals
treated prophylactically with L-826,141 did not develop EAE,
indicating that peripheral PDE4 inhibition was sufficient to
prevent the disease; 2) animals treated with rolipram, but
not L-826,141, displayed signs of sedation following admin-
istration of this PDE4 inhibitor and seemed to find the drug
increasingly aversive (resisted oral gavage) during the course
of the study; and 3) a lack of Fos activation in emetic regions
of the hindbrain following administration of L-826,141 (30
mg/kg p.o.) in EAE mice (data not shown). In addition, oral
administration of L-826,141 (30 mg/kg p.o.) fails to produce
emesis in ferrets (Frenette et al., 2002). Taken together,
these data suggest that the anti-inflammatory actions pro-
duced by oral administration of L-826,141 occurred periph-
erally, reducing the concern of emetic side effects in the
clinic.
Activation of the hypothalamic-pituitary-adrenal axis by
stress results in the release of endogenous glucocorticoids
that can alter susceptibility to certain autoimmune diseases
(Morale et al., 2001). In the EAE model, restraint stress has
been shown to have a significant impact on disease suppres-
sion in a murine model (Dowdell et al., 1999). In the present
experiment, the influence of restraint stress by oral gavage
on the suppression of EAE was investigated. Over a 12-day
period, using both a gavaged 1% methylcellulose group and a
nongavaged control, no significant differences in weight, dis-
ease onset, or clinical scores were recorded. It was therefore
concluded that restraint stress associated with oral gavage
did not influence the development and progression of EAE.
H&E and FluoroMyelin stains were performed on the spi-
nal cords of EAE animals to assess lymphocyte infiltration
and demyelination, respectively. Both of these hallmark fea-
tures of EAE were observed in mice that possessed elevated
clinical scores. As a method of assessing whether peripheral
PDE4 inhibition prevented this pathology, the presence of
demyelination and cellular infiltrates was examined in mice
that were administered L-826,141. Asymptomatic mice that
received L-826,141 (3 mg/kg p.o.) before the onset of clinical
signs of EAE did not possess these histopathological features
of EAE.
Following CNS trauma, inflammatory mediators, such as
TNF-, often contribute to astrogliosis and elevated GFAP
expression (Zhang et al., 2000; Kernie et al., 2001). Elevated
GFAP expression is observed in the CNS of MS patients and
may contribute to disease progression (Norgren et al., 2004).
GFAP immunoreactivity was assessed in the spinal cords of
EAE mice. Animals with elevated clinical scores showed an
increase in GFAP immunoreactivity, indicative of astroglio-
sis, in lumbar regions of the spinal cord. At doses sufficient to
attenuate or delay the onset of EAE, L-826,141 also de-
creased GFAP-positive immunoreactivity in the spinal cords
of these animals.
In vitro, PDE4 inhibition suppresses T-cell proliferation
and transendothelial migration and decreases production of
IL-2 and -4, IFN-, and TNF- (Gantner et al., 1997; Pette et
al., 1999). PDE4 inhibitors also suppress macrophage activa-
tion (Beshay et al., 2001) and TNF- release from monocytes
(Seldon et al., 1995). The development of a drug that does not
require entry into the CNS and also decreases T-cell activa-
tion, proliferation, and extravasation through the blood-
brain barrier would be extremely beneficial to those individ-
uals suffering from MS. The potency, low emetic potential,
inability to accumulate in the CNS, and anti-inflammatory
properties of L-826,141 make this compound a promising
therapeutic candidate for MS.
In summary, oral administration of 3 mg/kg L-826,141
significantly delayed the onset and decreased the severity of
EAE in C57BL/6 mice. After the initial symptoms of EAE
were observed, a higher dose of L-826,141 (30 mg/kg p.o.) was
required to significantly decrease EAE severity when admin-
istered 24 h after the onset of the first clinical signs of EAE.
Unlike many PDE4 inhibitors that have been previously
developed and tested in the EAE model, L-826,141 exerts its
mechanism of action in the periphery and does not cause
nausea and emesis. At doses that are anti-inflammatory,
these results demonstrate that peripheral PDE4 inhibition is
sufficient to suppress EAE pathogenesis, suggesting that
compounds with properties similar to L-826,141 may be use-
ful in the treatment of MS.
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